Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19849348 | 0.91 | ALDH1A1 (0.71) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL19849351 | 0.88 | SMN1; SMN2 (0.70) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL10723940 | 0.86 | DRD2 (0.65) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3021250 | 0.86 | LMNA (0.56) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL12820423 | 0.83 | GAA (0.54) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL13875530 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL26814786 | 0.82 | TSHR (0.64) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL14761461 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL12820388 | 0.81 | ALDH1A1 (0.59) | SMN1; SMN2GAAEPHX1MEN1KMT2A | |
| SCHEMBL10723369 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | SMN1; SMN2 3416/4885GAA 447/4885EPHX1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.